Translocator Protein PET/CT in Various TSPO-Related Disease

Launched by TIANJIN MEDICAL UNIVERSITY · Dec 5, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging technique called 18F-DPA714/FDPA PET/CT to see how well it can help diagnose certain diseases related to inflammation in the brain, stroke, and neurodegenerative conditions (like Alzheimer's). The goal is to find out if this method can effectively identify both primary tumors (the original cancer) and metastatic lesions (cancer that has spread from another part of the body) in patients.

To participate in the trial, you need to be an adult aged 18 or older, and you should have a suspected or newly diagnosed malignant tumor, which means a type of cancer. You'll also need to be scheduled for a TSPO PET/CT scan and be able to give your consent to join the study. However, if you have non-cancerous lesions, are pregnant, or cannot provide consent, you won't be eligible. If you decide to take part, you'll undergo the PET/CT scan, and the researchers will monitor and evaluate the results to help improve cancer diagnosis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled TSPO PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.